Krafton bets on Palworld Mobile to diversify from PUBG but commercial success remains uncertain Krafton hopes palworld mobile ...
− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing OSAKA, Japan & CAMBRIDGE, Mass., ...
Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody, mezagitamab (TAK-079), sustained kidney function up to 18 months after ...
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with ...
− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today ...
The Apple Watch is the most personal and powerful smartwatch you can buy, but its greatest strength—the sheer depth of the experience—is also its biggest challenge. Beyond the initial thrill of ...
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback